From the Department of Biology, San Diego State University Heart Institute and the Integrated Regenerative Research Institute, CA.
Circ Res. 2018 Jul 6;123(2):177-187. doi: 10.1161/CIRCRESAHA.118.311207.
The idiom heart of the matter refers to the focal point within a topic and, with regard to health and longevity, the heart is truly pivotal for quality of life. Societal trends worldwide continue toward increased percent body fat and decreased physical activity with coincident increases in chronic diseases including cardiovascular disease as the top global cause of death along with insulin resistance, accelerated aging, cancer. Although long-term survival rates for cardiovascular disease patients are grim, intense research efforts continue to improve both prevention and treatment options. Pharmacological interventions remain the predominant interventional strategy for mitigating progression and managing symptoms, but cellular therapies have the potential to cure or even mediate remission of cardiovascular disease. Adult stem cells are the most studied cellular therapy in both preclinical and clinical investigation. This review will focus on the advanced therapeutic strategies to augment products and methods of delivery, which many think heralds the future of clinical investigations. Advanced preclinical strategies using adult stem cells are examined to promote synergism between preclinical and clinical research, streamline implementation, and improve this imminent matter of the heart.
成语“问题的核心”是指一个主题的焦点,就健康和长寿而言,心脏对于生活质量确实至关重要。全球社会趋势继续朝着体脂百分比增加和身体活动减少的方向发展,同时慢性疾病包括心血管疾病的发病率也在增加,心血管疾病是全球死亡的首要原因,此外还有胰岛素抵抗、加速衰老和癌症。尽管心血管疾病患者的长期生存率不容乐观,但仍在继续进行大量研究工作,以改善预防和治疗选择。药物干预仍然是减轻进展和管理症状的主要介入策略,但细胞疗法有可能治愈甚至缓解心血管疾病。成体干细胞是临床前和临床研究中研究最多的细胞疗法。本综述将重点介绍增强产品和输送方法的先进治疗策略,许多人认为这预示着临床研究的未来。本文探讨了使用成体干细胞的先进临床前策略,以促进临床前和临床研究之间的协同作用,简化实施,并改善这一迫在眉睫的问题。